| Literature DB >> 22026997 |
Dae Won Kim1, Duk-Soo Kim, Mi Jin Kim, Soon Won Kwon, Eun Hee Ahn, Hoon Jae Jeong, Eun Jeong Sohn, Suman Dutta, Soon Sung Lim, Sung-Woo Cho, Kil Soo Lee, Jinseu Park, Won Sik Eum, Hyun Sook Hwang, Soo Young Choi.
Abstract
The protein transduction domains have been reported to have potential to deliver the exogenous molecules, including proteins, to living cells. However, poor transduction of proteins limits therapeutic application. In this study, we examined whether imipramine could stimulate the transduction efficiency of PEP-1 fused proteins into astrocytes. PEP-1-catalase (PEP-1- CAT) was transduced into astrocytes in a time- and dose-dependent manner, reducing cellular toxicity induced by H(2)O(2). Additionally, the group of PEP-1-CAT (+) imipramine showed enhancement of transduction efficiency and therefore increased cellular viability than that of PEP-1-CAT alone. In the gerbil ischemia models, PEP-1-CAT displayed significant neuroprotection in the CA1 region of the hippocampus. Interestingly, PEP-1-CAT (+) imipramine prevented neuronal cell death and lipid peroxidation more markedly than PEP-1-CAT alone. Therefore, our results suggest that imipramine can be used as a drug to enhance the transduction of PEP-1 fusion proteins to cells or animals and their efficacies against various disorders.Entities:
Mesh:
Substances:
Year: 2011 PMID: 22026997 DOI: 10.5483/BMBRep.2011.44.10.647
Source DB: PubMed Journal: BMB Rep ISSN: 1976-6696 Impact factor: 4.778